{"nctId":"NCT00553280","briefTitle":"A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy","startDateStruct":{"date":"2008-02"},"conditions":["Diabetic Neuropathy, Painful"],"count":123,"armGroups":[{"label":"pregabalin","type":"EXPERIMENTAL","interventionNames":["Drug: pregabalin"]}],"interventions":[{"name":"pregabalin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients who completed the 13-week treatment of painful diabetic peripheral neuropathy in Study A0081163.\n* Patients must be able to understand and cooperate with study procedures and have signed a written informed consent prior to entering the study\n\nExclusion Criteria:\n\n* Patients who experienced serious adverse events in the preceding study (A0081163) that were determined by the investigator or the study sponsor to be causally related to the study medication.\n* Patients exhibiting treatment non-compliance in the preceding study (A0081163)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Summary of Adverse Events","description":"Number of participants with all causality adverse events, serious adverse events, severe adverse events, adverse events resulted in discontinuation, dose reduced or temporary discontinuation. Participants are counted only once per treatment in each row.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"114","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Short-Form McGill Pain Questionnaire: Sensory Scores","description":"The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Sensory score ranges from 0-33. Higher scores indicate more severe pain.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.5","spread":"5.1"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Short-Form McGill Pain Questionnaire: Affective Scores","description":"The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Affective score ranges from 0-12. Higher scores indicate more severe pain.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"2.4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Short-Form McGill Pain Questionnaire: Total Scores","description":"The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Total score ranges from 0-45. Higher scores indicate more severe pain.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.7","spread":"6.8"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Short-Form McGill Pain Questionnaire: Visual Analogue Scale Scores","description":"The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Visual Analogue Scale Score ranges from 0-100 mm. Higher scores indicate more severe pain.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-25.4","spread":"26.4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Short-Form McGill Pain Questionnaire: Present Pain Intensity Scores","description":"The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Present pain intensity score ranges from 0-5. Higher scores indicate more severe pain.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"1.1"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":21,"n":123},"commonTop":["Nasopharyngitis","Weight increased","Somnolence","Dizziness","Oedema peripheral"]}}}